WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for SPRY

Based on 5 analysts offering 12 month price targets for Ars Pharmaceuticals Inc.
Min Forecast
$1.80-78.56%
Avg Forecast
$7.06-15.9%
Max Forecast
$14.00+66.77%

Should I buy or sell SPRY stock?

Based on 7 analysts offering ratings for Ars Pharmaceuticals Inc.
Hold
Strong Buy
0 analysts 0%
Buy
2 analysts 28.57%
Hold
5 analysts 71.43%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SPRY stock forecasts and price targets.

SPRY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Wedbush
Bottom 27%
27
BuyInitiates Coverage On$10.00+19.12%2023-01-31
SVB Leerink
Bottom 3%
3
BuyInitiates Coverage On$14.00+66.77%2022-12-13
Goldman Sachs
Bottom 8%
8
HoldDowngrades$3.50-58.31%2022-04-04
JonesTrading
Bottom 9%
9
HoldDowngradesN/AN/A2022-04-01
SVB Leerink
Bottom 1%
1
HoldDowngrades$1.80-78.56%2022-04-01
HC Wainwright & Co.
Bottom 19%
19
HoldDowngradesN/AN/A2022-04-01
Stifel Nicolaus
Bottom 8%
8
HoldDowngrades$6.00-28.53%2022-04-01

1 of 1

Forecast return on equity

Is SPRY forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is SPRY forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

SPRY earnings per share forecast

What is SPRY's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$2.09
Avg 2 year Forecast
-$1.69
Avg 3 year Forecast
-$0.72

SPRY revenue forecast

What is SPRY's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$31.3M
Avg 2 year Forecast
$87.5M
Avg 3 year Forecast
$77.5M

SPRY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRY$8.40$7.06-15.90%Hold
CRBU$4.88$29.80+510.66%Buy
STRO$5.11$21.00+310.96%Strong Buy
RANI$6.33$21.67+242.29%Strong Buy
AVIR$3.50$6.00+71.43%Sell

Ars Pharmaceuticals Stock Forecast FAQ

Is Ars Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: SPRY) stock is to Hold SPRY stock.

Out of 7 analysts, 0 (0%) are recommending SPRY as a Strong Buy, 2 (28.57%) are recommending SPRY as a Buy, 5 (71.43%) are recommending SPRY as a Hold, 0 (0%) are recommending SPRY as a Sell, and 0 (0%) are recommending SPRY as a Strong Sell.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.

What is SPRY's earnings growth forecast for 2023-2025?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Ars Pharmaceuticals's earnings in 2023 is -$85,384,000.On average, 1 Wall Street analyst forecast SPRY's earnings for 2023 to be -$75,361,926, with the lowest SPRY earnings forecast at -$75,361,926, and the highest SPRY earnings forecast at -$75,361,926. On average, 1 Wall Street analyst forecast SPRY's earnings for 2024 to be -$60,938,591, with the lowest SPRY earnings forecast at -$60,938,591, and the highest SPRY earnings forecast at -$60,938,591.

In 2025, SPRY is forecast to generate -$25,962,003 in earnings, with the lowest earnings forecast at -$25,962,003 and the highest earnings forecast at -$25,962,003.

What is SPRY's revenue growth forecast for 2024-2026?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Ars Pharmaceuticals's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast SPRY's revenue for 2024 to be $1,126,823,063, with the lowest SPRY revenue forecast at $1,126,823,063, and the highest SPRY revenue forecast at $1,126,823,063. On average, 1 Wall Street analysts forecast SPRY's revenue for 2025 to be $3,155,104,575, with the lowest SPRY revenue forecast at $3,155,104,575, and the highest SPRY revenue forecast at $3,155,104,575.

In 2026, SPRY is forecast to generate $2,794,521,195 in revenue, with the lowest revenue forecast at $2,794,521,195 and the highest revenue forecast at $2,794,521,195.

What is SPRY's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: SPRY) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is SPRY's Price Target?

According to 5 Wall Street analysts that have issued a 1 year SPRY price target, the average SPRY price target is $7.06, with the highest SPRY stock price forecast at $14.00 and the lowest SPRY stock price forecast at $1.80.

On average, Wall Street analysts predict that Ars Pharmaceuticals's share price could fall to $7.06 by Jan 31, 2024. The average Ars Pharmaceuticals stock price prediction forecasts a potential downside of 15.9% from the current SPRY share price of $8.40.

What is SPRY's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: SPRY) Ars Pharmaceuticals's current Earnings Per Share (EPS) is -$2.42. On average, analysts forecast that SPRY's EPS will be -$2.09 for 2023, with the lowest EPS forecast at -$2.09, and the highest EPS forecast at -$2.09. On average, analysts forecast that SPRY's EPS will be -$1.69 for 2024, with the lowest EPS forecast at -$1.69, and the highest EPS forecast at -$1.69. In 2025, SPRY's EPS is forecast to hit -$0.72 (min: -$0.72, max: -$0.72).

What is SPRY's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: SPRY) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.